Jefferies on Aligos Therapeutics Inc. (ALGS): 'looks cheap' ahead of Ph2 data
Tweet Send to a Friend
Jefferies analyst Anthea Li reiterated a Buy rating and $48.00 price target on Aligos Therapeutics Inc. (NASDAQ: ALGS)The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
